Overall survival† · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to lower overall survival† compared with anti‐CTLA4 monoclonal antibodies (high certainty).
1 finding from 1 review
HR 0.63 [0.6, 0.66]
764 participants
High
Progression‐free survival · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to lower progression‐free survival† compared with anti‐CTLA4 monoclonal antibodies (high certainty).
1 finding from 1 review
HR 0.54 [0.5, 0.6]
1465 participants
High
Tumour response · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to higher tumour response compared with anti‐CTLA4 monoclonal antibodies (high certainty).
1 finding from 1 review
RR 2.47 [2.01, 3.04]
1465 participants
High
Toxicity (≥ G3) · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies may leads to lower toxicity (≥ G3) compared with anti‐CTLA4 monoclonal antibodies (low certainty).
1 finding from 1 review
RR 0.7 [0.54, 0.91]
1465 participants
Low
Overall survival† · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in overall survival† compared with chemotherapy (low certainty).
1 finding from 1 review
HR 0.81 [0.65, 1.01]
1157 participants
Low
Change (improvement) in disease severity (4 to 8 weeks) SMD (modified EASI score and SASSAD) · eczema
1 finding from 1 review
Adverse effects (4 to 6 weeks) · eczema
1 finding from 1 review
Corticosteroid requirements · eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reduction of pruritus · eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in quality of life · eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for emollient use · eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Effect of long‐term control (> 3 months) · eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects (4 to 8 weeks) · eczema
1 finding from 1 review
Corticosteroid requirements · eczema
1 finding from 1 review
Reduction of pruritus · eczema
1 finding from 1 review
Improvement in quality of life · eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for emollient use · eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change (improvement) in disease severity (4 weeks) SCORAD score · eczema
1 finding from 1 review
Effect of long‐term control (> 3 months) · eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · NSTI
It is very uncertain whether moxifloxacin changes mortality compared with amoxicillin‐clavulanate (very low certainty).
1 finding from 1 review